Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.92 ^USD	+12.94%		-0.27%	+2.19%

Apr. 24	Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating	MT
Apr. 24	Transcript : Day One Biopharmaceuticals, Inc. - Special Call

Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 07, 2023 at 04:36 pm EDT

Day One Biopharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 45.86 million compared to USD 36.53 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to USD 0.6 a year ago.
For the six months, net loss was USD 88.26 million compared to USD 64.28 million a year ago. Basic loss per share from continuing operations was USD 1.2 compared to USD 1.08 a year ago.

Latest news about Day One Biopharmaceuticals, Inc.

Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating	Apr. 24	MT
Transcript : Day One Biopharmaceuticals, Inc. - Special Call	Apr. 24
Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma	Apr. 23	CI
Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment	Apr. 23	MT
Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval	Apr. 23	DJ
JPMorgan Raises Price Target on Day One Biopharmaceuticals to $36 From $32, Maintains Overweight Rating	Apr. 22	MT
Day One Biopharmaceuticals Insider Sold Shares Worth $322,166, According to a Recent SEC Filing	Feb. 29	MT
Piper Sandler Cuts Price Target on Day One Biopharmaceuticals to $40 From $45, Maintains Overweight Rating	Feb. 28	MT
Wedbush Adjusts Day One Biopharmaceuticals' Price Target to $33 From $35, Keeps Outperform Rating	Feb. 27	MT
Goldman Sachs Cuts Price Target on Day One Biopharmaceuticals to $44 From $50, Maintains Buy Rating	Feb. 27	MT
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Day One Biopharmaceuticals, Inc. Announces Executive Changes	Feb. 26	CI
Day One Biopharmaceuticals, Inc. Announces Board Appointments	Jan. 17	CI
Wedbush Lowers Day One Biopharmaceuticals' Price Target to $35 From $39, Keeps Outperform Rating	Nov. 07	MT
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy	23-10-31	MT
Wedbush Lifts Day One Biopharmaceuticals' PT to $39 From $38 After Tovorafenib Receives Priority Review, Maintains Outperform Rating	23-10-31	MT
Sector Update: Health Care Stocks Gain Late Afternoon	23-10-30	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-10-30	MT
Day One Biopharmaceuticals' New Drug Application for Tovorafenib Granted Priority Review by FDA	23-10-30	MT
Day One Biopharmaceuticals Shares Rally on FDA Priority Review	23-10-30	DJ
Day One Gets FDA Priority Review of Tovorafenib in Pediatric Brain Tumor	23-10-30	DJ
Day One Biopharmaceuticals, Inc. Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma	23-10-30	CI
Day One Biopharmaceuticals Files Mixed Shelf	23-09-15	MT
Sector Update: Health Care Stocks Higher Monday Afternoon	23-09-11	MT

Chart Day One Biopharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Companyâs lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Companyâs pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

14.92 USD

Average target price

36.89 USD

Spread / Average Target

+147.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DAY ONE BIOPHARMACEUTICALS, INC.	+2.19%	1.3B
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research